Skip to main content

Table 6 Incremental cost-effectiveness of 10- valent pneumococcal conjugate vaccine in terms of prevented ALRI incidence/1000-person years during three years follow-up from inclusion in the study in the intervention group, vaccinated sub-group (Sep. 2011 – Aug. 2012) and control group (Sep. 2009 – Aug. 2010) at Butajira rural health program site

From: Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation

Health outcomes

Cost*

Incremental cost

Effectiveness

Incremental effectiveness

Incremental cost- effectiveness ratio (ICER)

 

No discounting

Discounting 3%

Incidence of ALRI/1000-person years

  < 1 year of age

  Intervention

36.35

29.7

154.6

−46.6

Dominated

Dominated

  Vaccinated

34.0

27.39

154.5

−46.5

Dominated

Dominated

  Control

6.6

 

108.0

   

  > 1 year of age

  Intervention

29.3

26.4

56.4

3.96

6.7

7.5

  Vaccinated

28.7

25.9

30.6

29.8

0.9

1.0

  Control

2.83

 

60.4

   

  > 2 years of age

  Intervention

28.3

25.8

26.1

3.5

7.3

9.7

  Vaccinated

28.7

26.2

22.8

6.8

0.26

3.1

  Control

2.5

 

29.6

   

 Total follow-up period

27

     

  Intervention

39.7

28.1

88.5

−13.3

Dominated

Dominated

  Vaccinated

39.5

.9

82.1

−7.0

Dominated

Dominated

  Control

11.6

 

75.2

  Â